Proton therapy for adult-type diffuse glioma: A systematic review

Crit Rev Oncol Hematol. 2024 Dec:204:104501. doi: 10.1016/j.critrevonc.2024.104501. Epub 2024 Sep 7.

Abstract

Background: We conducted a systematic review to evaluate outcomes and toxicities associated with proton therapy in the treatment of adult-type diffuse glioma.

Methods: Following PRISMA guidelines, we searched PubMed for both prospective and retrospective studies on proton therapy for adult diffuse gliomas, including IDH-mutated gliomas WHO grade 2-3 and glioblastomas. Survival and toxicity outcomes were reported separately for these glioma types.

Results: Twelve studies from 2013 to 2023 were selected, comprising 3 prospective and 9 retrospective studies. The analysis covered 570 patients with WHO grade 2-3 gliomas and 240 patients with glioblastoma or WHO grade 4 gliomas. Proton therapy was found to be comparable to conventional radiotherapy in terms of survival outcomes. Its main advantage is the ability to minimize radiation exposure to healthy tissues.

Discussion: Proton therapy offers comparable survival outcomes to conventional radiotherapy for adult diffuse gliomas and may enhance treatment tolerance, especially regarding neurocognitive function. A major limitation of this review is the predominance of retrospective studies. Future research should ensure rigorous patient selection and adhere to the latest WHO 2021 classification.

Keywords: Glioblastoma; Glioma; Low grade glioma; Proton therapy; Radiotherapy; Systematic review.

Publication types

  • Systematic Review
  • Review

MeSH terms

  • Adult
  • Brain Neoplasms* / pathology
  • Brain Neoplasms* / radiotherapy
  • Brain Neoplasms* / therapy
  • Glioma* / pathology
  • Glioma* / radiotherapy
  • Glioma* / therapy
  • Humans
  • Proton Therapy* / adverse effects
  • Proton Therapy* / methods